High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy
Beate C. Litzenburger(Bristol-Myers Squibb (Germany)), Adrian V. Lee(Baylor College of Medicine), Michael T. Lewis(Baylor College of Medicine), Marco M. Gottardis(Georgetown University), Chad J. Creighton(Baylor College of Medicine), Fei Huang(Kyushu University), Mothaffar F. Rimawi(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Anna Tsimelzon(Pancreatic Cancer Action Network), Joan M. Carboni(Bristol-Myers Squibb (United States)), Bonita T. Chan(Bristol-Myers Squibb (Germany)), Tao Wang(Pfizer (United States)), Jenny C. Chang(Universität Hamburg)
Cited by 131
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k